Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05329623 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT05329623 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 33 participants.
The verdict
NCT05329623, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 in participants with varying degrees of hepatic impairment.
Interventions
- DRUG JDQ443
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-05-03 |
| Est. Completion | 2024-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05329623
The ClinicalTrials.gov registry entry for NCT05329623 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JDQ443 is the first listed.
NCT05329623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05329623 about?
NCT05329623 is a clinical study titled "A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.". The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 in participants with varying degrees of hepatic impairment.
What is the current status of trial NCT05329623?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2022-05-03. Estimated completion is 2024-04-07.
What interventions are being tested in trial NCT05329623?
The interventions under investigation include: JDQ443 (DRUG).
Who is sponsoring clinical trial NCT05329623?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.